BUSINESS● LOWSep 9 · Sep 9, 2026, 4:53 PM
Ocugen slips after interim trial data for Stargardt disease candidate
Seeking Alpha Tech · north america
Ocugen's stock declined following the release of interim trial data for its Stargardt disease candidate. This indicates a market reaction to the experimental treatment's progress.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS22m agoSEC Announces Fiscal Year 2027 Examination PrioritiesSECBUSINESS27m agoTamil Nadu cuts VAT rate on aviation turbine fuel at Chennai airport from 29% to 16%The Hindu